Treatment Patterns and Outcomes Before and After Humulin R U-500 Initiation Among US Patients with Type 2 Diabetes Previously Prescribed ≤ 200 Units/day of U-100 Insulin
Tóm tắt
Humulin R U-500 (U-500R) utilization has increased in the past few years, raising concerns as U-500R is indicated only for patients requiring > 200 units of insulin. Thus, evidence of dispensed total daily dose (dTDD) > 200 units of prior U-100 insulin based on pharmacy claims is increasingly used as a criterion to determine appropriate switching to U-500R by payers. The study compared the treatment patterns and outcomes before and after U-500R initiation among patients who were identified with ≤ 200 units/day U-100 insulin fill in order to understand the appropriateness of switching. Patients with type 2 diabetes who initiated U-500R (index date = first fill) with ≤ 200 units/day pre-index dTDD and > 200 units/day post-index dTDD were identified in a Veterans Health Administration dataset between 1 January 2014 and 30 June 2017. Descriptive analysis was conducted on treatment patterns (dTDD, insulin dosage [units/kg], adherence, number of prescription fills) and clinical outcomes (HbA1c, symptomatic hypoglycemic events). Associations between U-500R exposure and outcomes were evaluated using mixed-effects models. Subgroups of U-500R syringe and KwikPen users were analyzed separately. Among 1191 U-500R initiators identified in the study the mean dTDD increased from the pre- to post-index periods (147.2 vs 346.3; p < 0.0001). The mean HbA1c decreased from pre- to post-initiation (9.6% vs 8.6%; p < 0.0001), and symptomatic hypoglycemia events per patient per year increased (2.0 vs 3.3, p < 0.0001). Mixed-effects models confirmed the significance of the changes (p < 0.0001). Device subgroups followed similar trends. U-500R initiation was associated with large dTDD increases, improved glycemic control, and modest increases in hypoglycemia events, suggesting U-500R initiation may have corrected previous treatment compliance issues. Imposing dTDDs > 200 units before switching to U-500R criterion could hurt the opportunities for patients who need a simplified regimen for better outcomes.
Tài liệu tham khảo
Davies MJ, Gagliardino JJ, Gray LJ, Khunti K, Mohan V, Hughes R. Real-world factors affecting adherence to insulin therapy in patients with type 1 or type 2 diabetes mellitus: a systematic review. Diabet Med. 2013;30:512–24.
Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016;10:1299–307. https://doi.org/10.2147/PPA.S106821.
Hood RC, Arakaki RF, Wysham C, Li YG, Settles JA, Jackson JA. Two treatment approaches for human regular U-500 insulin in patients with type 2 diabetes not achieving adequate glycemic control on high-dose U-100 insulin therapy with or without oral agents: a randomized, titration-to-target clinical trial. Endocr Pract. 2015;21:782–93.
Hood RC, Williams S, Taneja D, Tannock LR. Clinical efficacy and patient satisfaction with U-500 insulin use. Diabetes Res Clin Pract. 2010;88:259–64.
Bulchandani DG, Konrady T, Hamburg MS. Clinical efficacy and patient satisfaction with U-500 insulin pump therapy in patients with type 2 diabetes. Endocr Pract. 2007;13:721–5.
Eby EL, Zagar AJ, Wang P, et al. Healthcare costs and adherence associated with human regular U-500 versus high-dose U-100 insulin in patients with diabetes. Endocr Pract. 2014;20:663–70.
FDA approves a dedicated syringe to be used with Humulin R U-500 insulin. U.S. Food and Drug Administration website. Last updated July 8, 2016. https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-dedicated-syringe-be-used-humulin-r-u-500-insulin. Accessed May 10, 2020.
Humulin R U-500 KwikPen may improve glycemic control in people with severely insulin-resistant diabetes [press release]. Indianapolis: Eli Lilly and Company; January 21, 2016. https://investor.lilly.com/releasedetail.cfm?ReleaseID=951175. Accessed Jan 21, 2016.
Sze D, Goldman J. Human regular 500 units/mL insulin therapy: a review of clinical evidence and new delivery options. Clin Diabetes. 2018;36(4):319–24.
Humuiln R Label 2018. United States Food & Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018780s126s134lbl.pdf. Accessed Aug 22, 2020.
Reutrakul S, Wroblewski K, Brown RL. Clinical use of U-500 regular insulin: review and meta-analysis. J Diabetes Sci Technol. 2012;6(2):412–20.
Al-Qazaz HK, Sulaiman SA, Hassali MA. Diabetes knowledge, medication adherence and glycemic control among patients with type 2 diabetes. Int J Clin Pharm. 2011;33(6):1028–35.
Cochran EK, Valentine V, Samaan KH, Corey IB, Jackson JA. Practice tips and tools for the successful use of U-500 regular human insulin: the diabetes educator is key. Diabetes Educ. 2014;40:153–65.
de la Peña A, Ma X, Reddy S, Ovalle F, Bergenstal RM, Jackson JA. Application of PK/PD modeling and simulation to dosing regimen optimization of high-dose human regular U-500 insulin. J Diabetes Sci Technol. 2014;8:821–9.
Schloot NC, Hood RC, Corrigan SM, Panek RL, Heise T. Concentrated insulins in current clinical practice. Diabetes Res Clin Pract. 2019;148:93–101.
Kabul S, Hood RC, Duan R, DeLozier AM, Settles J. Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial. Health Qual Life Outcomes. 2016;14(1):139.
Peng X, Chen J, Fan F, Ilag L, Ly T, Johnson J. Patient reported outcomes (PRO) in a study of human regular U-500 insulin (U-500R) delivered by continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI) in patients with T2D. Diabetes. 2018;67(S1):967.
Cummings DM, Lutes L, Littlewood K, et al. Regimen-related distress, medication adherence, and glycemic control in rural African American women with type 2 diabetes mellitus. Ann Pharmacother. 2014;48(8):970–7.
Hood RC, Borra S, Fan L, et al. Treatment patterns and outcomes, before and after Humulin R U-500 initiation, among high-dose type 2 diabetes mellitus patients in the United States. Endocr Pract. 2021;27(8):798–806.
Iskandar I, Peng X, Xuanyao H, et al. The trend of high-dose insulin usage among patients with diabetes in the UK: a retrospective study. Diabetes Ther. 2018;9(6):2245–57.
Stolpe S, Kroes MA, Webb N, Wisniewski T. A systematic review of insulin adherence measures in patients with diabetes. J Manag Care Spec Pharm. 2016;22(11):1224–46.
Choudhry NK, Shrank WH, Levin RL, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care. 2009;15(7):457–64.
Gibson TB, Song X, Alemayehu B, et al. Cost sharing, adherence, and health outcomes in patients with diabetes. Am J Manag Care. 2010;16(8):589–600.
Curtis S, Boye K, Lage M, et al. Medication adherence and improved outcomes among patients with type 2 diabetes. Am J Manag Care. 2017;23(7):e208–14.
Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American diabetes association workgroup on hypoglycemia. Diabetes Care. 2005;28(5):1245–9.
Ginde AA, Blanc PG, Lieberman RM, Camargo CA Jr. Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr Disord. 2008;8:4.
Huang YQ, Gou R, Diao YS, et al. Charlson comorbidity index helps predict the risk of mortality for patients with type 2 diabetic nephropathy. J Zhejiang Univ Sci B. 2014;15(1):58–66. https://doi.org/10.1631/jzus.B1300109.
Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;5(29):682–9.
Ovalle F. Clinical approach to the patient with diabetes mellitus and very high insulin requirements. Diabetes Res Clin Pract. 2010;90:231–42.
Wysham C, Hood RC, Warren ML, Wang T, Morwick TM, Jackson JA. Effect of total daily dose on efficacy, dosing, and safety of 2 dose titration regimens of human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes. Endocr Pract. 2016;22(6):653–65.
Chen J, Fan L, Pollom RD, et al. Insulin-related out-of-pocket pharmacy costs before and after human regular U-500 insulin initiation via insulin pen in U.S. patients with type 2 diabetes. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference 2020, Orlando, May 18–20, 2020.
Clancy ZA. MPR and PDC: implications for interpretation of adherence research results. Value Health. 2013;16(3):A53.
Chun J, Strong J, Urquhart S. Insulin initiation and titration in patients with type 2 diabetes. Diabetes Spectr. 2019;32(2):104–11. https://doi.org/10.2337/ds18-0005.
Blevins T, Lane W, Rodbard D, et al. Glucose variability and time in range in type 2 diabetes treated with U-500R by pump or injection: CGM findings from the VIVID study. Diabetes Technol Ther. 2020. https://doi.org/10.1089/dia.2020.0030.